Literature DB >> 15072795

Partition-controlled progesterone release from waterborne, in situ-gelling materials.

Brent L Vernon1, Frank Fusaro, Brad Borden, Kelly H Roy.   

Abstract

The primary goal of this work was to evaluate the long-term constant zero-order release of progesterone from a waterborne, in situ-gelling, injectable material. The motivation for this is to develop an intrafallopian tube embolization system for contraception. Poly(ethylene glycol) diacrylate (PEGDA, 575 g/mol) or poly(propylene glycol) diacrylate (PPODA, 540 g/mol) as a Michael-type addition acceptor was combined with pentaerythritol-tetrakis (3-mercaptopropionate; a Michael-type addition donor) to create a 75 wt.% emulsion solution in 0.1M PBS (pH 7.4 for PEGDA and pH 12 for PPODA) that gels in minutes by the Michael-type reaction to form a hydrophobic solid. Samples, with approximately 5.5 or 25 wt.% progesterone, were formed in Tygon tubing. Samples (1.6 mm x 1.0 cm cylinders) showed constant, partition-controlled release of progesterone for a prolonged period (time dependent on the mass of progesterone). Cylinders with approximately 25 wt.% load of progesterone exhibited constant release (approximately 40 microg per day) for more than 50 days in both the PEGDA and PPODA systems. This type of release is normally associated with preformed hydrophobic matrix systems. In contrast, these in situ-gelling materials reported here can be used to provide zero-order, partition-controlled release of progesterone and enhance the efficiency of an intrafallopian tube embolization system through progesterone release in an injectable, in situ-forming system.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15072795     DOI: 10.1016/j.ijpharm.2004.01.017

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  3 in total

1.  Thermoresponsive hydrogel as a delivery scaffold for transfected rat mesenchymal stem cells.

Authors:  Bradley A Borden; James Yockman; Sung Wan Kim
Journal:  Mol Pharm       Date:  2010-08-02       Impact factor: 4.939

2.  Formulation and evaluation of clindamycin HCL in situ gel for vaginal application.

Authors:  Priya Patel; Paresh Patel
Journal:  Int J Pharm Investig       Date:  2015 Jan-Mar

3.  Plasma-based fast-gelling biohybrid gels for biomedical applications.

Authors:  Amrita Pal; Kunal Tripathi; Chandrashekhar Pathak; Brent L Vernon
Journal:  Sci Rep       Date:  2019-07-26       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.